Cefixime for Respiratory Infections in Children

Limitations of Cefixime

• The American Academy of Otolaryngology explicitly states that cefixime has limited gram-positive coverage, including S. pneumoniae, and has no activity against drug-resistant S. pneumoniae (DRSP) 1
• Cefixime's predicted clinical efficacy in children with acute bacterial rhinosinusitis is only 82-87% (based on H. influenzae and M. catarrhalis coverage only), which is significantly lower than high-dose amoxicillin-clavulanate at 91-92% 3

Recommended First-Line Therapy

• The American Academy of Otolaryngology recommends high-dose amoxicillin (90 mg/kg/day) as the preferred first-line agent for children who have not received antibiotics in the previous 4-6 weeks 4
• The Pediatric Infectious Diseases Society recommends high-dose amoxicillin (90 mg/kg/day) for outpatient pneumonia in children under 5 years 5

Critical Errors to Avoid

• The American Academy of Otolaryngology advises against assuming all cephalosporins are equivalent for respiratory infections—cefixime's spectrum is fundamentally different from cefuroxime, cefpodoxime, or cefdinir 1
• The Infectious Diseases Society of America warns against using cefixime for suspected pneumococcal pneumonia—it lacks adequate coverage and may lead to treatment failure 2

Treatment Algorithm

• The American Academy of Otolaryngology recommends the following algorithm for pediatric bacterial respiratory infections: first-line therapy with high-dose amoxicillin (90 mg/kg/day) or high-dose amoxicillin-clavulanate (90 mg/6.4 mg per kg per day), and reserve cefixime for combination therapy in treatment failures or specific cases of pharyngitis/tonsillitis with documented S. pyogenes 4